Author

D. D. De Carvalho

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Cell Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:statistical model· 4 Assay:bulk RNA-seq· 3 Research Focus:differential expression· 3 Organism:human· 3 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:cell-cell communication· 1 Assay:DNA methylation· 1

Frequent Co-Authors

G. D. Bader· 2 shared S. A. Marhon· 2 shared A. A. Shishkin· 1 shared A. G. Trotman-Grant· 1 shared A. G. Zeng· 1 shared A. Hosseini· 1 shared A. J. Murison· 1 shared A. M. Joshua· 1 shared

Activity by Year

2020-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 19 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCell Biology

G. D. Bader

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Retroelement decay by the exonuclease XRN1 is a viral mimicry dependency in cancer

A. Hosseini, H. T. Lindholm, R. Chen, P. Mehdipour, S. A. Marhon, C. A. Ishak, D. D. De Carvalho

The paper identifies XRN1 as a dependency in cancer cells that control dsRNA stress through viral mimicry, revealing therapeutic opportunities.

bioRxiv · Mar 30, 2023Cell Biology

Identification of the Global miR-130a Targetome Reveals a Novel Role for TBL1XR1 in Hematopoietic Stem Cell Self-Renewal and t(8;21) AML

G. Krivdova, V. Voisin, E. M. Schoof, S. A. Marhon, A. J. Murison, J. L. McLeod, M. Gabra, A. G. Zeng, E. L. Van Nostrand, S. J. Aigner, A. A. Shishkin, B. A. Yee, K. G. Hermans, A. G. Trotman-Grant, N. Mbong, , E. R. Lechman

This study identifies miR-130a as a regulator of HSC self-renewal and differentiation, with TBL1XR1 as a key target, and shows its role in maintaining the oncogenic program in t(8;21) AML.

bioRxiv · Jul 30, 2021Cell Biology

Epigenetic reprogramming of plasmacytoid dendritic cells drives type I interferon-dependent differentiation of acute myeloid leukemias for therapeutic benefit

J. Salmon, I. Todorovski, S. J. Vervoort, K. L. Stanley, C. J. Kearney, L. Martelotto, F. Rossello, T. Semple, G. Mir Arnau, M. Zethoven, M. Bots, E. Vidacs, K. McArthur, E. Gressier, N. De Weerd, , R. W. Johnstone

The paper shows that inhibiting HDACs in AML promotes type I IFN production by pDCs, enhancing anti-tumor immunity and therapeutic benefit.

bioRxiv · Aug 23, 2020 · PreprintCancer Biology

Dynamics of the cell-free DNA methylome of metastatic prostate cancer during androgen-targeting treatment

M. R. Peter, M. Bilenky, R. Isserlin, G. D. Bader, S. Y. Shen, D. D. De Carvalho, A. R. Hansen, P. Hu, N. E. Fleshner, A. M. Joshua, M. Hirst, B. Bapat

This study examines methylation changes in cell-free DNA of mCRPC patients during androgen-targeting therapy, finding that persistent methylation changes correlate with longer time to clinical progression.

bioRxiv · Apr 8, 2020Cancer Biology